Altre lingue Akebia Therapeutics, Inc.

Azioni

AKBA

US00972D1054

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
1,37 ^USD	0,00%		-1,44%	+10,48%

16/04	Akebia Therapeutics, Inc. e STA Pharmaceutical Hong Kong Limited stipulano il secondo emendamento al Contratto di fornitura	CI
28/03	Aggiornamento settoriale: i titoli del settore sanitario avanzano giovedì prima del mercato	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Averoa Seeks EU Approval for Chronic Kidney Disease Drug	23/04
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	16/04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Sector Update: Health Care	28/03
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	28/03
Akebia Shares Rally Premarket After FDA Approves Vafseo	28/03
U.S. FDA approves Akebia's anemia drug	28/03
U.S. FDA approves Akebia's anemia drug	28/03
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis	28/03
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	28/03
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024	15/03
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024	15/03
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M	14/03
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	14/03
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	14/03
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	11/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Akebia Therapeutics, Inc.

Azioni

AKBA

US00972D1054

Altre lingue

Filtri